CVE-2023-40153: Dexma Dexgate

Medium severity, CVSS 6.1. EPSS: 0.4% chance of exploitation in the next 30 days.

The affected product is vulnerable to a cross-site scripting vulnerability, which could allow an attacker to access the web application to introduce arbitrary Java Script by injecting an XSS payload into the 'hostname' parameter of the vulnerable software.

Affected products

• Dexma Dexgate: version 20130114 only

Published 2023-10-19. Last modified 2026-06-17.